

# TABLE OF CONTENTS

<b>Atherosclerotic Cardiovascular Disease I</b> . . . . .	1
Atherosclerotic Cardiovascular Disease I Panel . . . . .	3
<b>Pharmacologic Prevention of Atherosclerotic Cardiovascular Events</b>	
<i>By Jonathan D. Cicci, Pharm.D., BCPS, BCCP, CPP; and Prashanth Iyer, Pharm.D., BCPS</i>	
Introduction . . . . .	7
Statins in Primary and Secondary Prevention . . . . .	7
Omega-3 Fatty Acids . . . . .	12
Aspirin in Secondary and Primary Prevention of ASCVD . . . . .	16
Conclusion . . . . .	21
References . . . . .	22
Self-Assessment Questions . . . . .	24
<b>Clinical Controversies in Therapeutic Targets</b>	
<i>By Michael S. Kelly, Pharm.D., FNLA, BCACP, CLS</i>	
Introduction . . . . .	29
Therapeutic Targets for Reducing ASCVD . . . . .	32
Coronary Artery Calcium Scoring for ASCVD Risk Estimation . . . . .	36
Uncertainties for Statin Use in Primary Prevention . . . . .	38
Efficacy and Safety of Very Low LDL-C . . . . .	43
Conclusion . . . . .	44
References . . . . .	44
Self-Assessment Questions . . . . .	47
<b>Atherosclerotic Cardiovascular Disease II</b> . . . . .	51
Atherosclerotic Cardiovascular Disease II Panel . . . . .	53
<b>Stable Atherosclerotic Cardiovascular Disease</b>	
<i>By Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP; and Maya R. Chilbert, Pharm.D., BCCP</i>	
Introduction . . . . .	57
Risk Factor Modification . . . . .	58
Stable Ischemic Heart Disease . . . . .	58
Peripheral Arterial Disease . . . . .	67
Atherosclerotic (Noncardioembolic) Ischemic Stroke or TIA . . . . .	77
Conclusion . . . . .	81
References . . . . .	82
Self-Assessment Questions . . . . .	87
<b>Acute Coronary Syndromes</b>	
<i>By Barbara S. Wiggins, Pharm.D., MBA, FAHA, FCCP, FACC, BCPS, BCCCP, BCCP, CLS; and Amy L. Lehnert, Pharm.D., BCPS, BCCP</i>	
Introduction . . . . .	91
ACS Defined . . . . .	92
Initial Assessment . . . . .	95
Risk Stratification . . . . .	96
Invasive vs. Noninvasive Strategies . . . . .	98
Pharmacologic Considerations . . . . .	98
Complications and Post-Management Considerations . . . . .	106
Secondary Prevention . . . . .	110
Conclusion . . . . .	118
References . . . . .	119
Self-Assessment Questions . . . . .	123
<b>Medication Management During PCI</b>	
<i>By James C. Coons, Pharm.D., FCCP, FACC, BCCP; and Nathan J. Verlinden, Pharm.D., BCPS, BCCP</i>	
Introduction . . . . .	127
Advances in PCI . . . . .	128
Oral and Intravenous Antiplatelets . . . . .	132
Periprocedural Anticoagulants . . . . .	143
Fibrinolytic Considerations . . . . .	145
Supportive Therapy for Post-PCI Complications . . . . .	145
Conclusion . . . . .	148
References . . . . .	149
Self-Assessment Questions . . . . .	156
<b>Atherosclerotic Cardiovascular Disease III</b> . . . . .	161
Atherosclerotic Cardiovascular Disease III Panel . . . . .	163
<b>Recorded Webcast: Applied Statistics in ASCVD</b>	
<i>By Benjamin Van Tassell, Pharm.D., FCCP, FAHA, BCPS, ASH-CHC</i>	
Recorded Webcast: Applied Statistics in ASCVD . . . . .	168
Hyperlink to activity . . . . .	168
Self-Assessment Questions . . . . .	169
<b>Interactive Case: Interpreting Biomarkers and Genomics in the Care of the CVD Patient</b>	
<i>By Yee Ming Lee, Pharm.D., BCPS, ABCP; and James C. Lee, Pharm.D., FCCP, AACC, BCACP</i>	
Interactive Case: Interpreting Biomarkers and Genomics in the Care of the Cardiovascular Patient . . . . .	174
Hyperlink to activity . . . . .	174
Self-Assessment Questions . . . . .	176